Based on these studies, it is reasonable to hypothesize that ERRα/γ transcriptional activation should ameliorate muscle contractility in congenital myopathies and prevent the decline of muscle strength (dynapenia) and mass (sarcopenia) during aging. The gene discussed is ESRRA; the disease is congenital myopathy with cores.